The first data on Nova21027 (Novagali Pharma), a benzalkonimum chloride (BAK)-free latanoprost cationic emulsion, have been announced at the Scientific Meeting of the Association for Ocular Pharmacology and Therapeutics (AOPT) in Salzburg, Austria.
The first data on Nova21027 (Novagali Pharma), a benzalkonimum chloride (BAK)-free latanoprost cationic emulsion, have been announced at this year's Scientific Meeting of the Association for Ocular Pharmacology and Therapeutics (AOPT) in Salzburg, Austria.
Professor Christophe Baudouin, of the Quinze-Vingts National Ophthalmology Hospital, Paris, France investigated the ocular surface toxicity of Nova21027 and compared the results with those of a BAK-containing anti-glaucoma eye drop.
Nova21027, which is stable at room temperature, demonstrated both safety and efficacy. The formula was found to have reduced ocular surface toxicity compared with the BAK-containing drops: it was well tolerated and did not damage the ocular surface under conditions of stress.
Novagali will present more data on Nova21027 at the 2009 meeting of the Association for Research in Vision and Ophthalmology (ARVO) in Fort Lauderdale, Florida in May.
AAO 2024: Transient vision loss with Alexander Fein, MD
October 21st 2024Alexander Fein, MD, spoke with the Eye Care Network to share how to approach a patient presenting with transient vision loss, what this type of vision loss can mean, and what additional testing might be needed to determine the best plan for care.
AAO 2024: Optimal pupil size reduction percentage for near vision improvement in presbyopia
October 21st 2024Jennifer Loh, MD, shared insights from on her presentation at the American Academy of Ophthalmology meeting in Chicago on the effects of CSF-1, which is the lowest effective concentration of pilocarpine approved in the United States.